

Effects of tomato-based foods on cardiovascular disease risk

Submission date 10/05/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 22/06/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 19/08/2022	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Frank Thies

Contact details
Polwarth Building
Foresterhill
Aberdeen
United Kingdom
AB25 2ZD
+44 (0)1224 553 020
f.thies@abdn.ac.uk

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
Effect of a tomato-rich diet on markers of cardiovascular risk in middle aged people: a single centre randomised controlled intervention study

Acronym

LYCTOM trial

Study objectives

10 mg daily lycopene consumption from a high tomato diet or lycopene supplementation can reduce markers for cardiovascular risk in middle aged people.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North of Scotland Research Ethics Committees approved on the 23rd May 2007 (ref: 07/S801/32)

Study design

Single centre single blind randomised controlled longitudinal intervention study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cardiovascular disease risk markers

Interventions

The dietary interventions proposed for this project are designed to compare three diets, each of which are practical and realistic for individuals to achieve. Each dietary intervention will be of 12 weeks duration.

1. Control group (diet limited in tomato-based foods):

The control group will be free to eat normally, but their intake of tomato-based foods will be restricted. They will not be allowed to consume any of the forbidden foods* listed below, but will be allowed to consume up to 1 portion of tomato soup, tomato juice or tomato sauce per week, and either:

- 1.1. Up to 4 raw tomatoes/24 cherry tomatoes per week, or
- 1.2. Up to 1 portion of tomato ketchup per week

2. Tomato group (diet rich in tomato-based foods):

The tomato group will be asked to consume a minimum of 70 mg lycopene per week from tomato-based foods which will be provided, including tomato juice, tomato ketchup, tomato sauce or tomato soup. Guidance will be provided on the number of portions needed to reach the required amount of lycopene intake using a points system. In addition, recipe suggestions can be provided for use of the tomato sauce, e.g. with pasta, with chicken and rice, with vegetables, in a bolognese sauce etc. The consumption of lycopene-equivalent tomato-based food should however not exceed 100 mg per week.

This group will not be allowed to consume any of the forbidden foods*, but will be allowed to consume, in addition to the soups/juices/sauces/ketchup, up to 4 raw tomatoes/24 cherry tomatoes per week.

3. Lycopene group (diet limited in tomato-based foods but supplemented with lycopene capsules):

The lycopene group will be free to eat normally, with the exception of consumption of forbidden foods, but will be supplemented with lycopene capsules (10 mg per day) to match the lycopene intake of the group consuming the tomato-rich foods.

*Forbidden foods:

Passata, canned tomatoes, cooked tomatoes (fried, grilled, etc.), tomato paste, tomato puree, pizza, salsa, chutney, canned beans/spaghetti/ravioli, etc., in tomato sauce, barbeque sauce, brown sauce, pink grapefruit, guava, watermelon, or apricots.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Lycopene

Primary outcome(s)

Serum total and low density lipoprotein (LDL) cholesterol and intercellular adhesion molecule 1 (ICAM-1) concentrations. All outcomes are measured four times during the study: prior run-in periods, at baseline (after run-in period), after 6 and 12 weeks intervention.

Key secondary outcome(s)

Insulin sensitivity as well as vascular function and inflammation markers (vascular tonicity by pulse-wave velocity, interleukin-6 [IL-6] and high sensitivity C-reactive protein [hsCRP]). All outcomes are measured four times during the study: prior run-in periods, at baseline (after run-in period), after 6 and 12 weeks intervention.

Completion date

31/08/2010

Eligibility

Key inclusion criteria

1. Men and women aged 40 - 65 years
2. Body mass index (BMI) between 25 and 35 kg/m²
3. Recruited from the surrounding community of Aberdeen
4. Sedentary or moderately active (less than two aerobic session per week)
5. Present signs of metabolic syndrome, e.g., if he/she has three or more of the following conditions:
 - 5.1. Fasting plasma glucose (greater than 6.1 mm/L)
 - 5.2. Triacylglycerol (TAG) level (greater than 1.7 mmol/L)
 - 5.3. Low high density lipoprotein (HDL) cholesterol (less than 1.04 mmol/L for men, less than 1.29 mmol/L for women)
 - 5.4. Hypertension (greater than 130/85 mmHg)
 - 5.5. Central obesity (waist circumference greater than 102 cm for men, greater than 88 cm for women)
 - 5.6. Moderate hypercholesterolaemia

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Cardiovascular disease (CVD)
2. Diabetes
3. Asthma
4. Systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 99 mmHg
5. Thyroid gland disorders or eating disorders
6. Regularly taking medication or supplements known to affect any dependant variable measured
7. High habitual intake of tomato-based food (greater than 5 servings per week)
8. Regularly taking nutritional supplements such as antioxidants or fish oil

Date of first enrolment

01/07/2007

Date of final enrolment

31/08/2010

Locations**Countries of recruitment**

United Kingdom

Scotland

Study participating centre**Polwarth Building**

Aberdeen

United Kingdom

AB25 2ZD

Sponsor information

Organisation

University of Aberdeen (UK)

ROR

<https://ror.org/016476m91>

Funder(s)

Funder type

Government

Funder Name

Food Standards Agency (UK) (ref: NO2038)

Alternative Name(s)

The Food Standards Agency, FSA

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2012		Yes	No
Results article		01/08/2022	19/08/2022	Yes	No